UK markets open in 4 hours 6 minutes

Agios Pharmaceuticals, Inc. (AGIO)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
29.43+0.40 (+1.38%)
At close: 04:00PM EDT
29.43 0.00 (0.00%)
After hours: 04:20PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close29.03
Open29.10
Bid29.36 x 300
Ask29.46 x 200
Day's range29.03 - 29.90
52-week range19.80 - 35.50
Volume549,245
Avg. volume740,366
Market cap1.654B
Beta (5Y monthly)0.86
PE ratio (TTM)N/A
EPS (TTM)-6.33
Earnings date02 May 2024
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est42.80
  • GlobeNewswire

    Agios to Webcast Conference Call of First Quarter 2024 Financial Results on May 2, 2024

    CAMBRIDGE, Mass., April 18, 2024 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and PK activation pioneering therapies for rare diseases, today announced the company will host a conference call and live webcast on Thursday, May 2, 2024, at 8:00 a.m. ET to report its first quarter 2024 financial results and other business highlights. A live webcast of the presentation can be accessed under "Events & Presentations" in the Investors section of the co

  • GuruFocus.com

    Director Jacqualyn Fouse Sells Shares of Agios Pharmaceuticals Inc (AGIO)

    Agios Pharmaceuticals Inc (NASDAQ:AGIO), a biopharmaceutical company focused on the discovery and development of novel therapies for the treatment of cancer and rare genetic diseases, has seen a recent insider transaction according to the latest SEC filings.

  • GlobeNewswire

    Agios Publishes 2024 Environmental, Social and Governance (ESG) Report

    – Report Highlights Company’s Focus on Red Blood Cell Health; Diversity, Equity & Inclusion; and Strong Corporate Governance – – Aligns with the Sustainability Accounting Standards Board (SASB) Standards for the Biotechnology and Pharmaceuticals Industry and the United Nations Sustainable Development Goals (UN SDGs) – CAMBRIDGE, Mass., April 09, 2024 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and PK activation pioneering therapies for rare dis